Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE1000062X2

Price
33.23 CNY
Market cap
29.78 bn CNY
P/E (2025)
10.12
P/S (2025)
7.09
Dividend yield
0.07 %
Net margin
69.98 %
Return on equity (ROE)
–
Return on assets (ROA)
32.81 %

Sunshine Guojian Pharmaceutical Shanghai Co Ltd financials

Fiscal year20242025
Revenue1.19 bn CNY4.20 bn CNY
Gross profit888.86 m CNY4.20 bn CNY
Operating income726.52 m CNY3.29 bn CNY
EBIT708.83 m CNY3.29 bn CNY
Net income704.58 m CNY2.94 bn CNY
Diluted EPS – continuing operations1.14 CNY4.76 CNY

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Sunshine Guojian Pharmaceutical Shanghai Co Ltd

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.

Sunshine Guojian Pharmaceutical Shanghai Co Ltd stock (688336.SS): P/E, revenue, dividend | finmetric